ArticleFrontiers in neurology2026
Resting-state EEG biomarkers of general and domain-specific cognitive impairment and plasma P-tau217 in patients with Alzheimer's disease and mild cognitive impairment.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early detection of Alzheimer's disease (AD)-related cognitive impairment remains challenging due to the lack of convenient, non-invasive screening tools. Objective: To explore the multidimensional utility of quantitative electroencephalography (EEG) as a complementary tool for early detection of AD-related cognitive impairment. Methods: Clinical data, electroencephalogram (EEG) records, cognitive scale scores and blood samples were collected. According to the established clinical diagnostic criteria, the participants were divided into three groups: cognitive normal group, mild cognitive impairment group (MCI) and Alzheimer's disease (AD) dementia group. Traditional statistical methods and machine learning algorithms were used to analyze the correlation between 200 EEG indexes and the severity of cognitive impairment, domain-specific cognitive impairment and plasma P-tau217 concentration. Results: A total of 360 participants (154 dementia patients with Alzheimer's disease, 116 mild cognitive impairment patients and 90 healthy controls) were included. The area under the curve (AUC) of EEG in 360 participants is 0.70-0.87, which can effectively distinguish cognitive dysfunction related to Alzheimer's disease. Among them, 102 participants improved the cognitive domain assessment scale, and the results showed that several EEG indexes were correlated with cognitive domain function score. The blood samples of 105 normal and MCI participants were tested for blood P-tau217 concentration. The relative power of right temporal lobe and right parietal lobe was negatively correlated with blood P-tau217 concentration, and the relative power of right parietal lobe was an independent influencing factor for the increase of blood P-tau217 level (AUC = 0.68). Conclusion: Quantitative EEG indicators show potential as a complementary screening approach for AD-related cognitive impairment. Further validation in prospective, multicenter cohorts is needed before implementation in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.